Volume -10 | Issue -2
Volume -10 | Issue -2
Volume -10 | Issue -2
Volume -10 | Issue -2
Volume -10 | Issue -2
Background: Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel disorders (IBD). Biological therapy uses monoclonal antibodies against chronic inflammatory disease targets. Aim: To determine the primary response rate, the primary non-response rate (PNR) & the secondary loss of response rate (SLR) to biologic agents in patients with IBD. Also, to determine the side effect profile of biologic agents in patients with IBD